nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2D6—Lomustine—brain cancer	0.174	0.282	CbGbCtD
Dexmedetomidine—CYP1A2—Carmustine—brain cancer	0.172	0.279	CbGbCtD
Dexmedetomidine—CYP2D6—Hydroxyurea—brain cancer	0.132	0.214	CbGbCtD
Dexmedetomidine—CYP2E1—Etoposide—brain cancer	0.0883	0.143	CbGbCtD
Dexmedetomidine—CYP1A2—Etoposide—brain cancer	0.0511	0.0827	CbGbCtD
Dexmedetomidine—Fluid overload—Carboplatin—brain cancer	0.00976	0.038	CcSEcCtD
Dexmedetomidine—Septic shock—Etoposide—brain cancer	0.0054	0.021	CcSEcCtD
Dexmedetomidine—Pleural effusion—Procarbazine—brain cancer	0.0044	0.0172	CcSEcCtD
Dexmedetomidine—Disorder sight—Temozolomide—brain cancer	0.00428	0.0167	CcSEcCtD
Dexmedetomidine—Metabolic acidosis—Etoposide—brain cancer	0.00413	0.0161	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Hydroxyurea—brain cancer	0.00411	0.016	CcSEcCtD
Dexmedetomidine—Nephropathy—Etoposide—brain cancer	0.00342	0.0133	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Procarbazine—brain cancer	0.0028	0.0109	CcSEcCtD
Dexmedetomidine—Haemoglobin—Lomustine—brain cancer	0.00268	0.0104	CcSEcCtD
Dexmedetomidine—Haemorrhage—Lomustine—brain cancer	0.00267	0.0104	CcSEcCtD
Dexmedetomidine—Visual impairment—Lomustine—brain cancer	0.00257	0.01	CcSEcCtD
Dexmedetomidine—Rigors—Temozolomide—brain cancer	0.0025	0.00973	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Temozolomide—brain cancer	0.00248	0.00966	CcSEcCtD
Dexmedetomidine—Blood urea increased—Hydroxyurea—brain cancer	0.00246	0.0096	CcSEcCtD
Dexmedetomidine—Speech disorder—Carmustine—brain cancer	0.00245	0.00956	CcSEcCtD
Dexmedetomidine—Speech disorder—Temozolomide—brain cancer	0.00237	0.00924	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Hydroxyurea—brain cancer	0.00232	0.00905	CcSEcCtD
Dexmedetomidine—Leukocytosis—Carmustine—brain cancer	0.00224	0.00875	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Temozolomide—brain cancer	0.00224	0.00874	CcSEcCtD
Dexmedetomidine—Infection—Carboplatin—brain cancer	0.00215	0.00838	CcSEcCtD
Dexmedetomidine—Respiratory failure—Temozolomide—brain cancer	0.00208	0.00809	CcSEcCtD
Dexmedetomidine—Sweating increased—Procarbazine—brain cancer	0.00206	0.00803	CcSEcCtD
Dexmedetomidine—SLC6A2—ganglion—brain cancer	0.00205	0.0696	CbGeAlD
Dexmedetomidine—Renal failure acute—Hydroxyurea—brain cancer	0.00205	0.00799	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Temozolomide—brain cancer	0.00204	0.00794	CcSEcCtD
Dexmedetomidine—Rigors—Etoposide—brain cancer	0.002	0.00779	CcSEcCtD
Dexmedetomidine—Apnoea—Etoposide—brain cancer	0.00192	0.0075	CcSEcCtD
Dexmedetomidine—Pneumonia—Procarbazine—brain cancer	0.0019	0.00739	CcSEcCtD
Dexmedetomidine—Infection—Lomustine—brain cancer	0.00188	0.00733	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Etoposide—brain cancer	0.00186	0.00723	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Lomustine—brain cancer	0.00185	0.00723	CcSEcCtD
Dexmedetomidine—Pain—Carboplatin—brain cancer	0.00185	0.00722	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Procarbazine—brain cancer	0.00185	0.0072	CcSEcCtD
Dexmedetomidine—Abnormal vision—Carmustine—brain cancer	0.00184	0.00717	CcSEcCtD
Dexmedetomidine—Sepsis—Carmustine—brain cancer	0.00183	0.00713	CcSEcCtD
Dexmedetomidine—Abnormal vision—Temozolomide—brain cancer	0.00178	0.00693	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carboplatin—brain cancer	0.00171	0.00667	CcSEcCtD
Dexmedetomidine—Haemoglobin—Procarbazine—brain cancer	0.0017	0.00663	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Temozolomide—brain cancer	0.0017	0.00663	CcSEcCtD
Dexmedetomidine—Haemorrhage—Procarbazine—brain cancer	0.00169	0.0066	CcSEcCtD
Dexmedetomidine—Hallucination—Procarbazine—brain cancer	0.00168	0.00656	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Etoposide—brain cancer	0.00163	0.00636	CcSEcCtD
Dexmedetomidine—Thirst—Temozolomide—brain cancer	0.00155	0.00606	CcSEcCtD
Dexmedetomidine—Chills—Procarbazine—brain cancer	0.00152	0.00592	CcSEcCtD
Dexmedetomidine—Arrhythmia—Procarbazine—brain cancer	0.00151	0.00589	CcSEcCtD
Dexmedetomidine—Body temperature increased—Lomustine—brain cancer	0.0015	0.00584	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Hydroxyurea—brain cancer	0.00143	0.00558	CcSEcCtD
Dexmedetomidine—Sepsis—Etoposide—brain cancer	0.00141	0.00552	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Carmustine—brain cancer	0.00139	0.00543	CcSEcCtD
Dexmedetomidine—Anaemia—Procarbazine—brain cancer	0.00136	0.00531	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Etoposide—brain cancer	0.00136	0.0053	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Temozolomide—brain cancer	0.00135	0.00525	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.00133	0.00519	CcSEcCtD
Dexmedetomidine—Haemoglobin—Hydroxyurea—brain cancer	0.00132	0.00513	CcSEcCtD
Dexmedetomidine—Haemorrhage—Hydroxyurea—brain cancer	0.00131	0.00511	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Temozolomide—brain cancer	0.0013	0.00509	CcSEcCtD
Dexmedetomidine—Hallucination—Hydroxyurea—brain cancer	0.0013	0.00508	CcSEcCtD
Dexmedetomidine—Abdominal distension—Temozolomide—brain cancer	0.00129	0.00502	CcSEcCtD
Dexmedetomidine—ADRA1D—telencephalon—brain cancer	0.00128	0.0435	CbGeAlD
Dexmedetomidine—Convulsion—Procarbazine—brain cancer	0.00128	0.00498	CcSEcCtD
Dexmedetomidine—Hypertension—Procarbazine—brain cancer	0.00127	0.00496	CcSEcCtD
Dexmedetomidine—Anxiety—Procarbazine—brain cancer	0.00125	0.00487	CcSEcCtD
Dexmedetomidine—Sweating increased—Temozolomide—brain cancer	0.00125	0.00485	CcSEcCtD
Dexmedetomidine—Dry mouth—Procarbazine—brain cancer	0.00123	0.00478	CcSEcCtD
Dexmedetomidine—Confusional state—Procarbazine—brain cancer	0.00121	0.00473	CcSEcCtD
Dexmedetomidine—Vomiting—Lomustine—brain cancer	0.0012	0.00469	CcSEcCtD
Dexmedetomidine—Infection—Procarbazine—brain cancer	0.00119	0.00466	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Carmustine—brain cancer	0.00119	0.00465	CcSEcCtD
Dexmedetomidine—Angiopathy—Hydroxyurea—brain cancer	0.00119	0.00463	CcSEcCtD
Dexmedetomidine—Pneumonia—Carmustine—brain cancer	0.00119	0.00462	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Procarbazine—brain cancer	0.00118	0.00459	CcSEcCtD
Dexmedetomidine—Chills—Hydroxyurea—brain cancer	0.00118	0.00458	CcSEcCtD
Dexmedetomidine—Tachycardia—Procarbazine—brain cancer	0.00117	0.00457	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Procarbazine—brain cancer	0.00116	0.00453	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Carmustine—brain cancer	0.00116	0.00451	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Temozolomide—brain cancer	0.00115	0.0045	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Carmustine—brain cancer	0.00115	0.00447	CcSEcCtD
Dexmedetomidine—Pneumonia—Temozolomide—brain cancer	0.00115	0.00447	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Etoposide—brain cancer	0.00113	0.00439	CcSEcCtD
Dexmedetomidine—Nausea—Lomustine—brain cancer	0.00112	0.00439	CcSEcCtD
Dexmedetomidine—Hypotension—Procarbazine—brain cancer	0.00112	0.00438	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Temozolomide—brain cancer	0.00112	0.00436	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Temozolomide—brain cancer	0.00111	0.00432	CcSEcCtD
Dexmedetomidine—Somnolence—Procarbazine—brain cancer	0.00107	0.00417	CcSEcCtD
Dexmedetomidine—Haemoglobin—Carmustine—brain cancer	0.00106	0.00415	CcSEcCtD
Dexmedetomidine—Haemorrhage—Carmustine—brain cancer	0.00106	0.00413	CcSEcCtD
Dexmedetomidine—Anaemia—Hydroxyurea—brain cancer	0.00105	0.00411	CcSEcCtD
Dexmedetomidine—Hallucination—Carmustine—brain cancer	0.00105	0.00411	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Etoposide—brain cancer	0.00104	0.00407	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Carmustine—brain cancer	0.00104	0.00407	CcSEcCtD
Dexmedetomidine—Haemoglobin—Temozolomide—brain cancer	0.00103	0.00401	CcSEcCtD
Dexmedetomidine—Pain—Procarbazine—brain cancer	0.00103	0.00401	CcSEcCtD
Dexmedetomidine—Constipation—Procarbazine—brain cancer	0.00103	0.00401	CcSEcCtD
Dexmedetomidine—Haemorrhage—Temozolomide—brain cancer	0.00102	0.00399	CcSEcCtD
Dexmedetomidine—Visual impairment—Carmustine—brain cancer	0.00102	0.00398	CcSEcCtD
Dexmedetomidine—Hallucination—Temozolomide—brain cancer	0.00102	0.00397	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Temozolomide—brain cancer	0.00101	0.00393	CcSEcCtD
Dexmedetomidine—Bronchospasm—Etoposide—brain cancer	0.00101	0.00392	CcSEcCtD
Dexmedetomidine—Sweating increased—Etoposide—brain cancer	0.000997	0.00388	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Procarbazine—brain cancer	0.000991	0.00386	CcSEcCtD
Dexmedetomidine—Convulsion—Hydroxyurea—brain cancer	0.000988	0.00385	CcSEcCtD
Dexmedetomidine—Visual impairment—Temozolomide—brain cancer	0.000986	0.00384	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Procarbazine—brain cancer	0.000983	0.00383	CcSEcCtD
Dexmedetomidine—Abdominal pain—Procarbazine—brain cancer	0.000951	0.00371	CcSEcCtD
Dexmedetomidine—Body temperature increased—Procarbazine—brain cancer	0.000951	0.00371	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Temozolomide—brain cancer	0.00095	0.0037	CcSEcCtD
Dexmedetomidine—Arrhythmia—Carmustine—brain cancer	0.000946	0.00369	CcSEcCtD
Dexmedetomidine—Angiopathy—Temozolomide—brain cancer	0.000928	0.00362	CcSEcCtD
Dexmedetomidine—Mental disorder—Carmustine—brain cancer	0.000928	0.00362	CcSEcCtD
Dexmedetomidine—Infection—Hydroxyurea—brain cancer	0.000925	0.0036	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Temozolomide—brain cancer	0.000922	0.00359	CcSEcCtD
Dexmedetomidine—Malnutrition—Carmustine—brain cancer	0.000922	0.00359	CcSEcCtD
Dexmedetomidine—Chills—Temozolomide—brain cancer	0.000918	0.00358	CcSEcCtD
Dexmedetomidine—Pneumonia—Etoposide—brain cancer	0.000917	0.00358	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Hydroxyurea—brain cancer	0.000911	0.00355	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Etoposide—brain cancer	0.000899	0.00351	CcSEcCtD
Dexmedetomidine—Mental disorder—Temozolomide—brain cancer	0.000896	0.00349	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Etoposide—brain cancer	0.000894	0.00349	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Etoposide—brain cancer	0.000894	0.00349	CcSEcCtD
Dexmedetomidine—SLC6A2—brainstem—brain cancer	0.000893	0.0303	CbGeAlD
Dexmedetomidine—Malnutrition—Temozolomide—brain cancer	0.000891	0.00347	CcSEcCtD
Dexmedetomidine—CYP2D6—hindbrain—brain cancer	0.000853	0.0289	CbGeAlD
Dexmedetomidine—Anaemia—Carmustine—brain cancer	0.000852	0.00332	CcSEcCtD
Dexmedetomidine—Agitation—Carmustine—brain cancer	0.000847	0.0033	CcSEcCtD
Dexmedetomidine—Dyspnoea—Hydroxyurea—brain cancer	0.00083	0.00323	CcSEcCtD
Dexmedetomidine—Somnolence—Hydroxyurea—brain cancer	0.000827	0.00322	CcSEcCtD
Dexmedetomidine—Anaemia—Temozolomide—brain cancer	0.000823	0.00321	CcSEcCtD
Dexmedetomidine—Diarrhoea—Procarbazine—brain cancer	0.000823	0.00321	CcSEcCtD
Dexmedetomidine—Agitation—Temozolomide—brain cancer	0.000819	0.00319	CcSEcCtD
Dexmedetomidine—ADRA1B—head—brain cancer	0.000817	0.0277	CbGeAlD
Dexmedetomidine—ADRA1D—endocrine gland—brain cancer	0.000809	0.0274	CbGeAlD
Dexmedetomidine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000803	0.00313	CcSEcCtD
Dexmedetomidine—ADRA1D—head—brain cancer	0.000799	0.0271	CbGeAlD
Dexmedetomidine—Convulsion—Carmustine—brain cancer	0.000799	0.00311	CcSEcCtD
Dexmedetomidine—Hypertension—Carmustine—brain cancer	0.000796	0.0031	CcSEcCtD
Dexmedetomidine—Pain—Hydroxyurea—brain cancer	0.000796	0.0031	CcSEcCtD
Dexmedetomidine—Constipation—Hydroxyurea—brain cancer	0.000796	0.0031	CcSEcCtD
Dexmedetomidine—Dizziness—Procarbazine—brain cancer	0.000795	0.0031	CcSEcCtD
Dexmedetomidine—SLC6A2—telencephalon—brain cancer	0.000793	0.0269	CbGeAlD
Dexmedetomidine—Anxiety—Carmustine—brain cancer	0.000782	0.00305	CcSEcCtD
Dexmedetomidine—Convulsion—Temozolomide—brain cancer	0.000772	0.00301	CcSEcCtD
Dexmedetomidine—Hypertension—Temozolomide—brain cancer	0.000769	0.003	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Hydroxyurea—brain cancer	0.000767	0.00299	CcSEcCtD
Dexmedetomidine—Vomiting—Procarbazine—brain cancer	0.000765	0.00298	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Etoposide—brain cancer	0.00076	0.00296	CcSEcCtD
Dexmedetomidine—Confusional state—Carmustine—brain cancer	0.000759	0.00296	CcSEcCtD
Dexmedetomidine—Rash—Procarbazine—brain cancer	0.000758	0.00296	CcSEcCtD
Dexmedetomidine—Dermatitis—Procarbazine—brain cancer	0.000757	0.00295	CcSEcCtD
Dexmedetomidine—Anxiety—Temozolomide—brain cancer	0.000756	0.00295	CcSEcCtD
Dexmedetomidine—Headache—Procarbazine—brain cancer	0.000753	0.00294	CcSEcCtD
Dexmedetomidine—Infection—Carmustine—brain cancer	0.000747	0.00291	CcSEcCtD
Dexmedetomidine—ADRA1B—central nervous system—brain cancer	0.000745	0.0253	CbGeAlD
Dexmedetomidine—Angiopathy—Etoposide—brain cancer	0.000743	0.0029	CcSEcCtD
Dexmedetomidine—Dry mouth—Temozolomide—brain cancer	0.000742	0.00289	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Etoposide—brain cancer	0.000738	0.00288	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Carmustine—brain cancer	0.000737	0.00287	CcSEcCtD
Dexmedetomidine—Body temperature increased—Hydroxyurea—brain cancer	0.000736	0.00287	CcSEcCtD
Dexmedetomidine—Chills—Etoposide—brain cancer	0.000735	0.00286	CcSEcCtD
Dexmedetomidine—Tachycardia—Carmustine—brain cancer	0.000734	0.00286	CcSEcCtD
Dexmedetomidine—Confusional state—Temozolomide—brain cancer	0.000733	0.00286	CcSEcCtD
Dexmedetomidine—ADRA1D—central nervous system—brain cancer	0.000729	0.0247	CbGeAlD
Dexmedetomidine—Infection—Temozolomide—brain cancer	0.000722	0.00282	CcSEcCtD
Dexmedetomidine—Nausea—Procarbazine—brain cancer	0.000714	0.00278	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Temozolomide—brain cancer	0.000712	0.00277	CcSEcCtD
Dexmedetomidine—Hypotension—Carmustine—brain cancer	0.000703	0.00274	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Temozolomide—brain cancer	0.000703	0.00274	CcSEcCtD
Dexmedetomidine—ADRA2C—telencephalon—brain cancer	0.000702	0.0238	CbGeAlD
Dexmedetomidine—Dyspnoea—Carmustine—brain cancer	0.000671	0.00261	CcSEcCtD
Dexmedetomidine—Somnolence—Carmustine—brain cancer	0.000669	0.00261	CcSEcCtD
Dexmedetomidine—SLC6A2—gonad—brain cancer	0.000661	0.0224	CbGeAlD
Dexmedetomidine—Anaemia—Etoposide—brain cancer	0.000659	0.00257	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Carmustine—brain cancer	0.000649	0.00253	CcSEcCtD
Dexmedetomidine—Dyspnoea—Temozolomide—brain cancer	0.000648	0.00253	CcSEcCtD
Dexmedetomidine—Somnolence—Temozolomide—brain cancer	0.000646	0.00252	CcSEcCtD
Dexmedetomidine—Constipation—Carmustine—brain cancer	0.000643	0.00251	CcSEcCtD
Dexmedetomidine—Pain—Carmustine—brain cancer	0.000643	0.00251	CcSEcCtD
Dexmedetomidine—Diarrhoea—Hydroxyurea—brain cancer	0.000637	0.00248	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000628	0.00245	CcSEcCtD
Dexmedetomidine—SLC6A2—medulla oblongata—brain cancer	0.000623	0.0211	CbGeAlD
Dexmedetomidine—Constipation—Temozolomide—brain cancer	0.000622	0.00242	CcSEcCtD
Dexmedetomidine—Pain—Temozolomide—brain cancer	0.000622	0.00242	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Carmustine—brain cancer	0.00062	0.00242	CcSEcCtD
Dexmedetomidine—Convulsion—Etoposide—brain cancer	0.000618	0.00241	CcSEcCtD
Dexmedetomidine—Hypertension—Etoposide—brain cancer	0.000615	0.0024	CcSEcCtD
Dexmedetomidine—Dizziness—Hydroxyurea—brain cancer	0.000615	0.0024	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Carmustine—brain cancer	0.000615	0.0024	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Temozolomide—brain cancer	0.000599	0.00234	CcSEcCtD
Dexmedetomidine—Abdominal pain—Carmustine—brain cancer	0.000595	0.00232	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carmustine—brain cancer	0.000595	0.00232	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Temozolomide—brain cancer	0.000594	0.00232	CcSEcCtD
Dexmedetomidine—ADRA1B—brain—brain cancer	0.000592	0.0201	CbGeAlD
Dexmedetomidine—Vomiting—Hydroxyurea—brain cancer	0.000592	0.00231	CcSEcCtD
Dexmedetomidine—Rash—Hydroxyurea—brain cancer	0.000587	0.00229	CcSEcCtD
Dexmedetomidine—Confusional state—Etoposide—brain cancer	0.000587	0.00229	CcSEcCtD
Dexmedetomidine—Dermatitis—Hydroxyurea—brain cancer	0.000586	0.00229	CcSEcCtD
Dexmedetomidine—Headache—Hydroxyurea—brain cancer	0.000583	0.00227	CcSEcCtD
Dexmedetomidine—ADRA1D—brain—brain cancer	0.000579	0.0196	CbGeAlD
Dexmedetomidine—Infection—Etoposide—brain cancer	0.000578	0.00225	CcSEcCtD
Dexmedetomidine—Body temperature increased—Temozolomide—brain cancer	0.000575	0.00224	CcSEcCtD
Dexmedetomidine—Abdominal pain—Temozolomide—brain cancer	0.000575	0.00224	CcSEcCtD
Dexmedetomidine—ADRA2C—pituitary gland—brain cancer	0.000572	0.0194	CbGeAlD
Dexmedetomidine—Thrombocytopenia—Etoposide—brain cancer	0.00057	0.00222	CcSEcCtD
Dexmedetomidine—Tachycardia—Etoposide—brain cancer	0.000568	0.00221	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Etoposide—brain cancer	0.000562	0.00219	CcSEcCtD
Dexmedetomidine—ADRA2A—telencephalon—brain cancer	0.00056	0.019	CbGeAlD
Dexmedetomidine—Nausea—Hydroxyurea—brain cancer	0.000553	0.00215	CcSEcCtD
Dexmedetomidine—ADRA2C—medulla oblongata—brain cancer	0.000552	0.0187	CbGeAlD
Dexmedetomidine—CYP2E1—telencephalon—brain cancer	0.000548	0.0186	CbGeAlD
Dexmedetomidine—Hypotension—Etoposide—brain cancer	0.000544	0.00212	CcSEcCtD
Dexmedetomidine—Dyspnoea—Etoposide—brain cancer	0.000519	0.00202	CcSEcCtD
Dexmedetomidine—Somnolence—Etoposide—brain cancer	0.000517	0.00202	CcSEcCtD
Dexmedetomidine—Diarrhoea—Carmustine—brain cancer	0.000515	0.00201	CcSEcCtD
Dexmedetomidine—ADRA2C—midbrain—brain cancer	0.000504	0.0171	CbGeAlD
Dexmedetomidine—Gastrointestinal disorder—Etoposide—brain cancer	0.000502	0.00196	CcSEcCtD
Dexmedetomidine—SLC6A2—endocrine gland—brain cancer	0.0005	0.0169	CbGeAlD
Dexmedetomidine—Dizziness—Carmustine—brain cancer	0.000497	0.00194	CcSEcCtD
Dexmedetomidine—Pain—Etoposide—brain cancer	0.000497	0.00194	CcSEcCtD
Dexmedetomidine—Constipation—Etoposide—brain cancer	0.000497	0.00194	CcSEcCtD
Dexmedetomidine—Diarrhoea—Temozolomide—brain cancer	0.000497	0.00194	CcSEcCtD
Dexmedetomidine—SLC6A2—head—brain cancer	0.000494	0.0167	CbGeAlD
Dexmedetomidine—ADRA2C—spinal cord—brain cancer	0.000492	0.0167	CbGeAlD
Dexmedetomidine—CYP2D6—brainstem—brain cancer	0.000489	0.0166	CbGeAlD
Dexmedetomidine—Dizziness—Temozolomide—brain cancer	0.000481	0.00187	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Etoposide—brain cancer	0.000479	0.00187	CcSEcCtD
Dexmedetomidine—Vomiting—Carmustine—brain cancer	0.000478	0.00186	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Etoposide—brain cancer	0.000476	0.00185	CcSEcCtD
Dexmedetomidine—Rash—Carmustine—brain cancer	0.000474	0.00185	CcSEcCtD
Dexmedetomidine—Dermatitis—Carmustine—brain cancer	0.000474	0.00185	CcSEcCtD
Dexmedetomidine—Headache—Carmustine—brain cancer	0.000471	0.00184	CcSEcCtD
Dexmedetomidine—ADRA2A—gonad—brain cancer	0.000468	0.0158	CbGeAlD
Dexmedetomidine—Vomiting—Temozolomide—brain cancer	0.000462	0.0018	CcSEcCtD
Dexmedetomidine—Body temperature increased—Etoposide—brain cancer	0.00046	0.00179	CcSEcCtD
Dexmedetomidine—Abdominal pain—Etoposide—brain cancer	0.00046	0.00179	CcSEcCtD
Dexmedetomidine—Rash—Temozolomide—brain cancer	0.000458	0.00179	CcSEcCtD
Dexmedetomidine—Dermatitis—Temozolomide—brain cancer	0.000458	0.00179	CcSEcCtD
Dexmedetomidine—ADRA2A—pituitary gland—brain cancer	0.000456	0.0155	CbGeAlD
Dexmedetomidine—Headache—Temozolomide—brain cancer	0.000455	0.00178	CcSEcCtD
Dexmedetomidine—SLC6A2—central nervous system—brain cancer	0.00045	0.0153	CbGeAlD
Dexmedetomidine—Nausea—Carmustine—brain cancer	0.000447	0.00174	CcSEcCtD
Dexmedetomidine—ADRA2A—medulla oblongata—brain cancer	0.00044	0.0149	CbGeAlD
Dexmedetomidine—ADRA2C—head—brain cancer	0.000437	0.0148	CbGeAlD
Dexmedetomidine—CYP2D6—telencephalon—brain cancer	0.000434	0.0147	CbGeAlD
Dexmedetomidine—Nausea—Temozolomide—brain cancer	0.000432	0.00168	CcSEcCtD
Dexmedetomidine—CYP2E1—medulla oblongata—brain cancer	0.000431	0.0146	CbGeAlD
Dexmedetomidine—ADRA2A—midbrain—brain cancer	0.000402	0.0136	CbGeAlD
Dexmedetomidine—ADRA2C—central nervous system—brain cancer	0.000399	0.0135	CbGeAlD
Dexmedetomidine—Diarrhoea—Etoposide—brain cancer	0.000398	0.00155	CcSEcCtD
Dexmedetomidine—ADRA2A—spinal cord—brain cancer	0.000393	0.0133	CbGeAlD
Dexmedetomidine—ADRA2C—cerebellum—brain cancer	0.00039	0.0132	CbGeAlD
Dexmedetomidine—Dizziness—Etoposide—brain cancer	0.000385	0.0015	CcSEcCtD
Dexmedetomidine—CYP1A2—endocrine gland—brain cancer	0.000384	0.013	CbGeAlD
Dexmedetomidine—CYP2E1—spinal cord—brain cancer	0.000384	0.013	CbGeAlD
Dexmedetomidine—CYP1A1—endocrine gland—brain cancer	0.000379	0.0128	CbGeAlD
Dexmedetomidine—CYP1A1—head—brain cancer	0.000374	0.0127	CbGeAlD
Dexmedetomidine—Vomiting—Etoposide—brain cancer	0.00037	0.00144	CcSEcCtD
Dexmedetomidine—Rash—Etoposide—brain cancer	0.000367	0.00143	CcSEcCtD
Dexmedetomidine—Dermatitis—Etoposide—brain cancer	0.000366	0.00143	CcSEcCtD
Dexmedetomidine—Headache—Etoposide—brain cancer	0.000364	0.00142	CcSEcCtD
Dexmedetomidine—SLC6A2—brain—brain cancer	0.000358	0.0121	CbGeAlD
Dexmedetomidine—ADRA2A—endocrine gland—brain cancer	0.000353	0.012	CbGeAlD
Dexmedetomidine—ADRA2A—head—brain cancer	0.000349	0.0118	CbGeAlD
Dexmedetomidine—CYP2E1—endocrine gland—brain cancer	0.000346	0.0117	CbGeAlD
Dexmedetomidine—Nausea—Etoposide—brain cancer	0.000346	0.00135	CcSEcCtD
Dexmedetomidine—CYP1A1—central nervous system—brain cancer	0.000342	0.0116	CbGeAlD
Dexmedetomidine—CYP2E1—head—brain cancer	0.000341	0.0116	CbGeAlD
Dexmedetomidine—ADRA2A—central nervous system—brain cancer	0.000318	0.0108	CbGeAlD
Dexmedetomidine—ADRA2C—brain—brain cancer	0.000317	0.0107	CbGeAlD
Dexmedetomidine—CYP2E1—central nervous system—brain cancer	0.000312	0.0106	CbGeAlD
Dexmedetomidine—ADRA2A—cerebellum—brain cancer	0.000311	0.0105	CbGeAlD
Dexmedetomidine—CYP2E1—cerebellum—brain cancer	0.000304	0.0103	CbGeAlD
Dexmedetomidine—CYP2D6—endocrine gland—brain cancer	0.000274	0.00927	CbGeAlD
Dexmedetomidine—CYP1A1—brain—brain cancer	0.000271	0.00919	CbGeAlD
Dexmedetomidine—CYP2D6—head—brain cancer	0.00027	0.00916	CbGeAlD
Dexmedetomidine—ADRA2A—brain—brain cancer	0.000253	0.00857	CbGeAlD
Dexmedetomidine—CYP2E1—brain—brain cancer	0.000247	0.00838	CbGeAlD
Dexmedetomidine—CYP2D6—central nervous system—brain cancer	0.000247	0.00836	CbGeAlD
Dexmedetomidine—CYP2D6—cerebellum—brain cancer	0.000241	0.00817	CbGeAlD
Dexmedetomidine—CYP2D6—brain—brain cancer	0.000196	0.00664	CbGeAlD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—TRPC6—brain cancer	7.81e-05	0.00081	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—BSG—brain cancer	7.77e-05	0.000806	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—TRPC6—brain cancer	7.71e-05	0.0008	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GLI2—brain cancer	7.7e-05	0.000799	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VAV1—brain cancer	7.64e-05	0.000792	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PTCH1—brain cancer	7.58e-05	0.000787	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—SMO—brain cancer	7.58e-05	0.000787	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	7.56e-05	0.000784	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—SHH—brain cancer	7.47e-05	0.000775	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—brain cancer	7.42e-05	0.000769	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP2C9—brain cancer	7.42e-05	0.000769	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—SHH—brain cancer	7.35e-05	0.000763	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GLI1—brain cancer	7.24e-05	0.000751	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—TRPC6—brain cancer	7.21e-05	0.000747	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ABR—brain cancer	7.2e-05	0.000747	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—TRPC6—brain cancer	7.09e-05	0.000736	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—SMO—brain cancer	7.08e-05	0.000735	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PTCH1—brain cancer	7.08e-05	0.000735	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—VAV1—brain cancer	7.05e-05	0.000731	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—SMO—brain cancer	6.97e-05	0.000723	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PTCH1—brain cancer	6.97e-05	0.000723	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTCH2—brain cancer	6.96e-05	0.000722	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GLI2—brain cancer	6.95e-05	0.000721	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—brain cancer	6.93e-05	0.000719	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SUFU—brain cancer	6.86e-05	0.000712	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP2C9—brain cancer	6.81e-05	0.000707	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HES5—brain cancer	6.74e-05	0.000699	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ABR—brain cancer	6.72e-05	0.000697	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	6.72e-05	0.000697	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—IDH1—brain cancer	6.68e-05	0.000693	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—brain cancer	6.62e-05	0.000687	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GFAP—brain cancer	6.62e-05	0.000687	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ABR—brain cancer	6.62e-05	0.000686	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STRADA—brain cancer	6.54e-05	0.000679	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GLI1—brain cancer	6.54e-05	0.000678	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GLI2—brain cancer	6.49e-05	0.000674	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—TRPC6—brain cancer	6.44e-05	0.000668	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP2C9—brain cancer	6.42e-05	0.000666	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—VAV1—brain cancer	6.4e-05	0.000664	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—PIK3CG—brain cancer	6.39e-05	0.000663	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GLI2—brain cancer	6.39e-05	0.000663	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—VAV1—brain cancer	6.36e-05	0.00066	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—BSG—brain cancer	6.31e-05	0.000654	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HEY1—brain cancer	6.28e-05	0.000651	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	6.27e-05	0.000651	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SUFU—brain cancer	6.2e-05	0.000643	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—DLL1—brain cancer	6.16e-05	0.000638	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GLI1—brain cancer	6.11e-05	0.000633	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—SHH—brain cancer	6.07e-05	0.00063	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GLI1—brain cancer	6.01e-05	0.000623	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GFAP—brain cancer	5.98e-05	0.00062	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—PIK3CG—brain cancer	5.97e-05	0.00062	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—VAV1—brain cancer	5.94e-05	0.000617	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—TRPC6—brain cancer	5.85e-05	0.000607	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—VAV1—brain cancer	5.85e-05	0.000607	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—BSG—brain cancer	5.79e-05	0.000601	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SUFU—brain cancer	5.79e-05	0.0006	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—VAV1—brain cancer	5.78e-05	0.000599	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PTCH1—brain cancer	5.75e-05	0.000597	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—SMO—brain cancer	5.75e-05	0.000597	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SUFU—brain cancer	5.7e-05	0.000591	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HEY1—brain cancer	5.67e-05	0.000588	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—brain cancer	5.63e-05	0.000584	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GFAP—brain cancer	5.58e-05	0.000579	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—DLL1—brain cancer	5.56e-05	0.000576	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GFAP—brain cancer	5.5e-05	0.00057	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ABR—brain cancer	5.46e-05	0.000566	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—BSG—brain cancer	5.46e-05	0.000566	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—IDH1—brain cancer	5.42e-05	0.000563	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—VAV1—brain cancer	5.4e-05	0.00056	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—VAV1—brain cancer	5.31e-05	0.000551	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HEY1—brain cancer	5.29e-05	0.000549	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ENO2—brain cancer	5.28e-05	0.000548	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GLI2—brain cancer	5.27e-05	0.000547	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SHH—brain cancer	5.23e-05	0.000543	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HEY1—brain cancer	5.21e-05	0.00054	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—DLL1—brain cancer	5.19e-05	0.000538	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—DLL1—brain cancer	5.11e-05	0.00053	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TRPC6—brain cancer	5.05e-05	0.000523	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—IDH1—brain cancer	4.98e-05	0.000517	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTCH1—brain cancer	4.96e-05	0.000515	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SMO—brain cancer	4.96e-05	0.000515	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GLI1—brain cancer	4.96e-05	0.000514	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PIK3CG—brain cancer	4.85e-05	0.000503	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP2C9—brain cancer	4.83e-05	0.000501	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—VAV1—brain cancer	4.83e-05	0.000501	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SHH—brain cancer	4.73e-05	0.00049	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SUFU—brain cancer	4.7e-05	0.000488	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—IDH1—brain cancer	4.7e-05	0.000487	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TRPC6—brain cancer	4.56e-05	0.000473	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GFAP—brain cancer	4.54e-05	0.00047	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—IL2—brain cancer	4.5e-05	0.000467	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SMO—brain cancer	4.48e-05	0.000465	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTCH1—brain cancer	4.48e-05	0.000465	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CG—brain cancer	4.48e-05	0.000464	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SHH—brain cancer	4.41e-05	0.000458	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—VAV1—brain cancer	4.39e-05	0.000455	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SHH—brain cancer	4.34e-05	0.000451	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HEY1—brain cancer	4.3e-05	0.000446	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ENO2—brain cancer	4.29e-05	0.000445	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TRPC6—brain cancer	4.26e-05	0.000441	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—DLL1—brain cancer	4.22e-05	0.000437	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—IL2—brain cancer	4.2e-05	0.000436	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TRPC6—brain cancer	4.19e-05	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTCH1—brain cancer	4.18e-05	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SMO—brain cancer	4.18e-05	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTCH1—brain cancer	4.12e-05	0.000427	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SMO—brain cancer	4.12e-05	0.000427	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—BSG—brain cancer	4.11e-05	0.000426	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2C9—brain cancer	4.1e-05	0.000425	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CG—brain cancer	4.06e-05	0.000422	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CG—brain cancer	4.04e-05	0.000419	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOTCH2—brain cancer	3.97e-05	0.000411	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ENO2—brain cancer	3.94e-05	0.000408	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—VEGFA—brain cancer	3.82e-05	0.000397	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.82e-05	0.000397	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VAV1—brain cancer	3.78e-05	0.000392	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CG—brain cancer	3.77e-05	0.000392	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CG—brain cancer	3.72e-05	0.000385	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ENO2—brain cancer	3.71e-05	0.000385	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CG—brain cancer	3.67e-05	0.000381	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SHH—brain cancer	3.59e-05	0.000372	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH2—brain cancer	3.58e-05	0.000371	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—VEGFA—brain cancer	3.57e-05	0.000371	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—IDH1—brain cancer	3.53e-05	0.000367	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—BSG—brain cancer	3.48e-05	0.000361	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TRPC6—brain cancer	3.46e-05	0.000359	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CG—brain cancer	3.43e-05	0.000356	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VAV1—brain cancer	3.41e-05	0.000354	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—IL2—brain cancer	3.41e-05	0.000354	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTCH1—brain cancer	3.4e-05	0.000353	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SMO—brain cancer	3.4e-05	0.000353	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CG—brain cancer	3.37e-05	0.00035	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH2—brain cancer	3.35e-05	0.000347	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH2—brain cancer	3.29e-05	0.000341	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HES1—brain cancer	3.25e-05	0.000337	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VAV1—brain cancer	3.19e-05	0.000331	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—IL2—brain cancer	3.15e-05	0.000327	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VAV1—brain cancer	3.14e-05	0.000326	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PDGFRA—brain cancer	3.1e-05	0.000321	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CG—brain cancer	3.07e-05	0.000318	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SPP1—brain cancer	3.01e-05	0.000312	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—IDH1—brain cancer	2.99e-05	0.000311	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HES1—brain cancer	2.94e-05	0.000305	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VEGFA—brain cancer	2.9e-05	0.000301	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—brain cancer	2.89e-05	0.0003	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL2—brain cancer	2.86e-05	0.000297	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—IL2—brain cancer	2.84e-05	0.000295	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PDGFRA—brain cancer	2.8e-05	0.00029	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ENO2—brain cancer	2.79e-05	0.00029	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CG—brain cancer	2.78e-05	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HES1—brain cancer	2.74e-05	0.000284	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IRS2—brain cancer	2.72e-05	0.000282	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH2—brain cancer	2.72e-05	0.000282	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SPP1—brain cancer	2.71e-05	0.000282	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HES1—brain cancer	2.7e-05	0.00028	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—brain cancer	2.7e-05	0.00028	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—IL2—brain cancer	2.66e-05	0.000276	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—IL2—brain cancer	2.61e-05	0.000271	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PDGFRA—brain cancer	2.61e-05	0.000271	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VAV1—brain cancer	2.59e-05	0.000269	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL2—brain cancer	2.58e-05	0.000268	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PDGFRA—brain cancer	2.57e-05	0.000267	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SPP1—brain cancer	2.54e-05	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SPP1—brain cancer	2.5e-05	0.000259	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IRS2—brain cancer	2.45e-05	0.000255	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.44e-05	0.000253	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CG—brain cancer	2.42e-05	0.000251	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL2—brain cancer	2.41e-05	0.00025	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—APC—brain cancer	2.4e-05	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CG—brain cancer	2.4e-05	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL2—brain cancer	2.37e-05	0.000246	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ENO2—brain cancer	2.37e-05	0.000246	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IRS2—brain cancer	2.29e-05	0.000238	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IRS2—brain cancer	2.26e-05	0.000234	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HES1—brain cancer	2.23e-05	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—brain cancer	2.19e-05	0.000227	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—brain cancer	2.19e-05	0.000227	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CG—brain cancer	2.17e-05	0.000225	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APC—brain cancer	2.17e-05	0.000225	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—brain cancer	2.16e-05	0.000224	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PDGFRA—brain cancer	2.12e-05	0.00022	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SPP1—brain cancer	2.06e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APC—brain cancer	2.02e-05	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CG—brain cancer	2.02e-05	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APC—brain cancer	1.99e-05	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CG—brain cancer	1.99e-05	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—brain cancer	1.98e-05	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CG—brain cancer	1.97e-05	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—brain cancer	1.96e-05	0.000203	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RELA—brain cancer	1.88e-05	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—brain cancer	1.86e-05	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IRS2—brain cancer	1.86e-05	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—brain cancer	1.84e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—brain cancer	1.82e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—brain cancer	1.81e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—brain cancer	1.7e-05	0.000177	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RELA—brain cancer	1.69e-05	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—brain cancer	1.69e-05	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—brain cancer	1.68e-05	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—brain cancer	1.65e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—brain cancer	1.64e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—brain cancer	1.64e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—brain cancer	1.63e-05	0.000169	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RELA—brain cancer	1.58e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—brain cancer	1.57e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RELA—brain cancer	1.56e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—brain cancer	1.55e-05	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—brain cancer	1.53e-05	0.000158	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—brain cancer	1.5e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—brain cancer	1.49e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—brain cancer	1.47e-05	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—brain cancer	1.44e-05	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—brain cancer	1.43e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—brain cancer	1.42e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—brain cancer	1.4e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—brain cancer	1.39e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—brain cancer	1.38e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—brain cancer	1.37e-05	0.000142	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—brain cancer	1.35e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—brain cancer	1.32e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—brain cancer	1.3e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—brain cancer	1.29e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RELA—brain cancer	1.29e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—brain cancer	1.28e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—brain cancer	1.28e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—brain cancer	1.28e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—brain cancer	1.21e-05	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—brain cancer	1.2e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—brain cancer	1.19e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—brain cancer	1.19e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—brain cancer	1.18e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—brain cancer	1.17e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—brain cancer	1.16e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—brain cancer	1.13e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—brain cancer	1.12e-05	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—brain cancer	1.11e-05	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—brain cancer	1.1e-05	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—brain cancer	1.09e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—brain cancer	1.09e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—brain cancer	1.09e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—brain cancer	1.07e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—brain cancer	9.84e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—brain cancer	9.8e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—brain cancer	9.74e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—brain cancer	9.15e-06	9.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—brain cancer	9.05e-06	9.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—brain cancer	9.01e-06	9.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—brain cancer	8.85e-06	9.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—brain cancer	7.43e-06	7.71e-05	CbGpPWpGaD
